MX388906B - Derivados quinoxalinona de la fórmula (i) que presentan actividad reguladoras sobre cftr. - Google Patents
Derivados quinoxalinona de la fórmula (i) que presentan actividad reguladoras sobre cftr.Info
- Publication number
- MX388906B MX388906B MX2018007768A MX2018007768A MX388906B MX 388906 B MX388906 B MX 388906B MX 2018007768 A MX2018007768 A MX 2018007768A MX 2018007768 A MX2018007768 A MX 2018007768A MX 388906 B MX388906 B MX 388906B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cftr
- regulators
- cftr regulators
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
En el presente documento se proporcionan compuestos que activan el CFTR y métodos para tratar el estreñimiento, trastornos de sequedad de ojos, y otras enfermedades y trastornos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387579P | 2015-12-24 | 2015-12-24 | |
| US201662376808P | 2016-08-18 | 2016-08-18 | |
| PCT/US2016/068566 WO2017112950A1 (en) | 2015-12-24 | 2016-12-23 | Cftr regulators and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX388906B true MX388906B (es) | 2025-03-20 |
Family
ID=59091221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007768A MX388906B (es) | 2015-12-24 | 2016-12-23 | Derivados quinoxalinona de la fórmula (i) que presentan actividad reguladoras sobre cftr. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11084795B2 (es) |
| EP (2) | EP3394046B1 (es) |
| JP (2) | JP6938509B2 (es) |
| KR (1) | KR102743295B1 (es) |
| CN (1) | CN108699040B (es) |
| AU (1) | AU2016377785B2 (es) |
| BR (1) | BR112018012934B1 (es) |
| CA (1) | CA3009534A1 (es) |
| CL (1) | CL2018001716A1 (es) |
| CO (1) | CO2018007236A2 (es) |
| DK (1) | DK3394046T3 (es) |
| ES (1) | ES2913051T3 (es) |
| IL (1) | IL260212B (es) |
| MX (1) | MX388906B (es) |
| PL (1) | PL3394046T3 (es) |
| PT (1) | PT3394046T (es) |
| RU (1) | RU2730855C2 (es) |
| WO (1) | WO2017112950A1 (es) |
| ZA (1) | ZA201804229B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3394040T (pt) | 2015-12-24 | 2022-03-24 | Univ California | Reguladores de cftr e seus métodos de uso |
| US11084795B2 (en) | 2015-12-24 | 2021-08-10 | The Regents Of The University Of California | CFTR regulators and methods of use thereof |
| CN111629730A (zh) * | 2017-08-24 | 2020-09-04 | 加利福尼亚大学董事会 | 眼部药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0008864A1 (en) | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| ZA794209B (en) * | 1978-08-15 | 1980-07-30 | Fisons Ltd | Pharmaceutically active heterocyclic compounds |
| US4181724A (en) | 1978-09-11 | 1980-01-01 | The Upjohn Company | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| FR2653430B1 (fr) | 1989-10-23 | 1991-12-20 | Pf Medicament | Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique. |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6369057B1 (en) | 1991-04-15 | 2002-04-09 | Aventis Pharma Deutschland Gmbh | Quinoxalines, processes for their preparation and their use |
| WO1994011355A1 (fr) | 1992-11-19 | 1994-05-26 | Dainippon Pharmaceutical Co., Ltd. | Derive de 3,4-dihydro-1(2-hydroxyphenyl)-2(1h)-quinoxalinone et compose associe |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| JP2002509923A (ja) | 1998-03-31 | 2002-04-02 | ワーナー−ランバート・カンパニー | Ｘａ因子およびトロンビンのようなセリンプロテアーゼ阻害剤としてのキノキサリノン |
| US6908921B2 (en) | 2002-12-13 | 2005-06-21 | Merck & Co., Inc. | Quinoxalinone derivatives as bradykinin B1 antagonists |
| DE102004023332A1 (de) * | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| US8263607B2 (en) * | 2007-05-22 | 2012-09-11 | Astellas Pharma Inc. | 1-substituted tetrahydroisoquinoline compound |
| US8415352B2 (en) * | 2008-03-05 | 2013-04-09 | MERCK Patent Gesellschaft mit beschränkter Haftung | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| AU2009308232B2 (en) * | 2008-10-23 | 2016-02-04 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2015007940A (es) * | 2012-12-19 | 2016-03-11 | Novartis Ag | Compuestos tricíclicos como inhibidores de cftr. |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| US11084795B2 (en) | 2015-12-24 | 2021-08-10 | The Regents Of The University Of California | CFTR regulators and methods of use thereof |
-
2016
- 2016-12-23 US US16/016,281 patent/US11084795B2/en active Active
- 2016-12-23 ES ES16880159T patent/ES2913051T3/es active Active
- 2016-12-23 PT PT168801595T patent/PT3394046T/pt unknown
- 2016-12-23 WO PCT/US2016/068566 patent/WO2017112950A1/en not_active Ceased
- 2016-12-23 AU AU2016377785A patent/AU2016377785B2/en active Active
- 2016-12-23 DK DK16880159.5T patent/DK3394046T3/da active
- 2016-12-23 KR KR1020187021223A patent/KR102743295B1/ko active Active
- 2016-12-23 PL PL16880159T patent/PL3394046T3/pl unknown
- 2016-12-23 BR BR112018012934-8A patent/BR112018012934B1/pt active IP Right Grant
- 2016-12-23 EP EP16880159.5A patent/EP3394046B1/en active Active
- 2016-12-23 MX MX2018007768A patent/MX388906B/es unknown
- 2016-12-23 CN CN201680082473.8A patent/CN108699040B/zh active Active
- 2016-12-23 RU RU2018126957A patent/RU2730855C2/ru active
- 2016-12-23 JP JP2018533117A patent/JP6938509B2/ja active Active
- 2016-12-23 EP EP22159301.5A patent/EP4071140B1/en active Active
- 2016-12-23 CA CA3009534A patent/CA3009534A1/en active Pending
-
2018
- 2018-06-21 CL CL2018001716A patent/CL2018001716A1/es unknown
- 2018-06-21 IL IL260212A patent/IL260212B/en unknown
- 2018-06-22 ZA ZA2018/04229A patent/ZA201804229B/en unknown
- 2018-07-11 CO CONC2018/0007236A patent/CO2018007236A2/es unknown
-
2021
- 2021-04-08 US US17/226,004 patent/US12503447B2/en active Active
- 2021-08-31 JP JP2021141178A patent/JP7297828B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| IL248732B (en) | Compounds for the treatment of ophthalmological diseases and disorders | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2020011749A (es) | Composiciones y metodos para modular la expresion de pkk. | |
| MX2021006439A (es) | Reguladores del cftr y metodos para su uso. | |
| EP3662903A3 (en) | Combination therapies | |
| EP3261620A4 (en) | Methods and compositions for treating dry eye disease and other eye disorders | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
| WO2016077639A3 (en) | Nanovesicular therapies | |
| IL267229A (en) | Methods of treating ocular disorders | |
| EP3310358A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SUBSTANCE ABUSE, SEARCH AND PSYCHIATRIC DISORDER | |
| PH12017500602A1 (en) | Methods for treating ocular conditions | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| MX388906B (es) | Derivados quinoxalinona de la fórmula (i) que presentan actividad reguladoras sobre cftr. | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| HK40025989A (en) | Methods of treating neuropsychiatric disorders | |
| HK40021785A (en) | Methods for treating complement-mediated diseases and disorders | |
| AU2016905227A0 (en) | Treatment of iron disorders | |
| AU2017902346A0 (en) | Methods of treating ocular disorders | |
| HK1261774A1 (en) | Methods for treating eye disorders | |
| HK40003860A (en) | Methods of treating mitochondrial disorders |